Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 83% primary Improvement Relative Risk Case (b) -4% c19ivm.org Behera et al. Ivermectin for COVID-19 Prophylaxis Does ivermectin reduce COVID-19 infections? Prospective study of 3,346 patients in India Fewer cases with ivermectin (p=0.001) Behera et al., Cureus 13:8, doi:10.7759/cureus.16897 Favors ivermectin Favors control
Prophylactic Role of Ivermectin in Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare Workers
Behera et al., Cureus 13:8, doi:10.7759/cureus.16897 (date from earlier preprint)
Behera et al., Prophylactic Role of Ivermectin in Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare.., Cureus 13:8, doi:10.7759/cureus.16897 (date from earlier preprint)
Feb 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective prophylaxis study with 3,532 healthcare workers, 2,199 receiving two-dose ivermectin prophylaxis, showing adjusted relative risk of confirmed COVID-19 with treatment 0.17 [0.12-0.23] p<0.001. 186 patients took only the first dose, and no significant difference was observed for this group. The same group published an earlier small study with 117 ivermectin patients. There were no serious adverse events. T/IM-NF/CM&FM/20/142.
risk of case, 83.0% lower, RR 0.17, p < 0.001, treatment 45 of 2,199 (2.0%), control 133 of 1,147 (11.6%), NNT 10, two doses, primary outcome.
risk of case, 4.0% higher, RR 1.04, p = 0.85, treatment 23 of 186 (12.4%), control 133 of 1,147 (11.6%), patients only receiving the first dose.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Behera et al., 15 Feb 2021, prospective, India, peer-reviewed, 14 authors, dosage 300μg/kg days 1, 4.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Open Access Original Article DOI: 10.7759/cureus.16897 Prophylactic Role of Ivermectin in Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare Workers Priyamadhaba Behera 1 , Binod K. Patro 1 , Biswa M. Padhy 2 , Prasanta R. Mohapatra 3 , Shakti K. Bal 3 , Pradnya D. Chandanshive 1 , Rashmi R. Mohanty 4 , SR Ravikumar 1 , Arvind Singh 1 , Sudipta R. Singh 5 , Siva Santosh Kumar Pentapati 1 , Jyolsna Nair 1 , Gitanjali Batmanbane 6 1. Community Medicine and Family Medicine, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, IND 2. Pharmacology, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, IND 3. Pulmonary Medicine and Critical Care, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, IND 4. General Medicine, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, IND 5. Forensic Medicine, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, IND 6. Medicine, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, IND Corresponding author: Gitanjali Batmanbane, director@aiimsbhubaneswar.edu.in Abstract
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit